Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community
JAMA, 07/02/09
Melander O et al. – Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events.
Methods- Study of the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors
- Cohort study of 5067 pts (mean age, 58 yrs; 60% women) without cardiovascular disease from Malmö, Sweden, who had baseline examination between 1991-1994
- Measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP)
- Follow-up until 2006 using Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death)
- Main outcome measures: incident cardiovascular and coronary events
- During median follow-up of 12.8 yrs, 418 cardiovascular and 230 coronary events
- Models with conventional risk factors had C statistics of 0.758 and 0.760 for cardiovascular and coronary events, respectively
- Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased C statistic by 0.007 and 0.009, respectively
- Modest proportion of pts reclassified: 8% for cardiovascular risk, 5% for coronary risk
- Net reclassification improvement: nonsignificant for cardiovascular events and coronary events
- Greater improvements in analyses restricted to intermediate-risk pts
- Correct reclassification almost entirely confined to down-classification of pts without events vs up-classification of pts with events
Related Articles
Extremes of Endogenous Testosterone Are Associated with Increased Risk of Incident Coronary Events in Older Women
Journal of Clinical Endocrinology and Metabolism, 11/30/09
Relevance Score: 80%%
Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study
Arthritis & Rheumatism, 11/05/09
Relevance Score: 70%%
CRESTOR reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study
AstraZeneca, 11/18/09
Relevance Score: 69%%
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09
Relevance Score: 67%%
Chronic renal insufficiency, cardiovascular disease and mortality in women: a causal relationship or coincidence?
Women's Health, 11/02/09
Relevance Score: 67%%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Altered Hepatic Gene Expression Profiles Associated with Myocardial Ischemia
Circulation: Cardiovascular Genetics, 12/02/09
Predictive value of electrical restitution in hypokalemia-induced ventricular arrhythmogenicity
Heart And Circulatory Physiology, 11/19/09
The Cellular Prion Protein Identifies Bipotential Cardiomyogenic Progenitors
Circulation Research, 11/18/09
Today in Coronary Artery Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Usefulness of Pregnancy-Associated Plasma Protein A in Patients With Acute Coronary Syndrome
The American Journal of Cardiology, 12/02/09
Advances in Antiplatelet Treatment for Acute Coronary Syndromes
Heart, 12/02/09
Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)
The American Journal of Cardiology, 12/02/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


